Chimeric immunoglobulin-T-cell receptor (IgTCR)-modified T cells (“designer T cells”) kill tumor cells based on antibody-redirected recognition of tumor-associated antigen. Anti-carcinoembryonic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results